Literature DB >> 17098535

Risk factors for restenosis after carotid artery angioplasty and stenting.

Christopher L Skelly1, Katherine Gallagher, Ronald M Fairman, Jeffrey P Carpenter, Omaida C Velazquez, Shane S Parmer, Edward Y Woo.   

Abstract

OBJECTIVES: With carotid artery stenting (CAS) becoming an ever-increasing procedure, we sought to determine risk factors for in-stent restenosis after CAS.
METHODS: Consecutive patients undergoing CAS between January 2002 and October 2004 at a tertiary care hospital were retrospectively reviewed. Patient, filter, and stent selection were left to the discretion of the attending surgeon. High-risk patients were defined by significant comorbidities or a hostile neck (prior surgery or radiation, or both), and risk factor analysis was performed. In-stent restenosis was defined as >60%, and selective angiography was performed on patients with an in-stent restenosis >80% by duplex ultrasound imaging.
RESULTS: Reviewed were 101 patients (55 men, 46 women) who underwent 109 CAS procedures. Comorbidities were typical for patients with atherosclerosis. In addition, 38% (n = 41) of procedures were performed in patients who had prior neck surgery, of which 29% (n = 32) had previous ipsilateral carotid endarterectomy. Seventeen patients (16%) had a history of neck cancer, and all had prior neck radiation. Median follow-up was 5 months (range, 0 to 30 months). Neurologic complications included three transient ischemic attacks (2.8%) and one nondisabling stroke (0.9%). There were two myocardial infarctions (1.9%) and no periprocedural deaths (30 days), for a combined stroke, myocardial infarction, and death rate of 2.9%. Asymptomatic in-stent restenosis developed in 12 carotids (11%), five of which required endovascular intervention, with a mean of 6 months to restenosis. Univariate Cox proportional hazard regression models were used to determine risk factors for the development of restenosis. Prior stroke, transient ischemic attack, amaurosis fugax, and prior neck cancer were all significant risk factors. When these significant risk factors from univariate analysis were put into multivariate analysis, however, the only marginally significant risk factor was prior neck cancer (P = .06). Kaplan-Meier analysis revealed a cumulative freedom from in-stent restenosis at 24 months of 88% +/- 6% in patients without neck cancer compared with 27% +/- 17% (P = .02) in patients with neck cancer.
CONCLUSIONS: CAS has been shown to be safe and effective in high-risk patients, with minimal adverse events.

Entities:  

Mesh:

Year:  2006        PMID: 17098535     DOI: 10.1016/j.jvs.2006.07.039

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  11 in total

1.  Carotid artery interventions for restenosis after prior stenting: is it different from interventions of de novo lesions? Results from the carotid artery stent (CAS)--registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).

Authors:  Ralf Zahn; Thomas Ischinger; Uwe Zeymer; Johannes Brachmann; Jens Jung; Hartwig Haase; Karl Eugen Hauptmann; Hubert Seggewiss; Ilse Janicke; Matthias Leschke; Harald Mudra
Journal:  Clin Res Cardiol       Date:  2010-07-02       Impact factor: 5.460

2.  The incidence of carotid in-stent stenosis is underestimated ≥50% or ≥80% and its clinical implications.

Authors:  Ali F AbuRahma; Zachary T AbuRahma; Grant Scott; Elliot Adams; Abe Mata; Matthew Beasley; L Scott Dean; Elaine Davis
Journal:  J Vasc Surg       Date:  2018-12-11       Impact factor: 4.268

3.  Factors affecting long-term restenosis after carotid stenting for carotid atherosclerotic disease.

Authors:  Jai Jai Shiva Shankar; Jingwen Zhang; Marlise dos Santos; Howard Lesiuk; Ravi Mohan; Cheemun Lum
Journal:  Neuroradiology       Date:  2012-04-21       Impact factor: 2.804

4.  Influence of the hostile neck on restenosis after carotid stenting.

Authors:  Kevin A Brown; Dina S Itum; Yazan Duwayri; James G Reeves; Ravi Rajani; Ravi K Veeraswamy; Shipra Arya; Atef Salam; Thomas F Dodson; Luke P Brewster
Journal:  Ann Vasc Surg       Date:  2014-06-12       Impact factor: 1.466

5.  Long-term outcome after angioplasty of symptomatic internal carotid artery stenosis with and without stent.

Authors:  O Wittkugel; J Gbadamosi; M Rosenkranz; J Fiehler; H Zeumer; U Grzyska
Journal:  Neuroradiology       Date:  2007-10-25       Impact factor: 2.804

6.  A case of in-stent neoatherosclerosis 10 years after carotid artery stent implantation: observation with optical coherence tomography and plaque histological findings.

Authors:  Hiroyuki Matsumoto; Rie Yako; Osamu Masuo; Katsuhisa Hirayama; Yuji Uematsu; Naoyuki Nakao
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-20       Impact factor: 1.742

7.  Investigation factors affecting the first recurrence of coronary artery disease in patients undergone angioplasty using cox survival model.

Authors:  Javad Nasseryan; Ebrahim Hajizadeh; Aliakbar Rasekhi; Hassan Ahangar
Journal:  Med J Islam Repub Iran       Date:  2016-11-08

Review 8.  New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease.

Authors:  Kurt Brassington; Stavros Selemidis; Steven Bozinovski; Ross Vlahos
Journal:  Clin Sci (Lond)       Date:  2019-04-12       Impact factor: 6.124

9.  Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial.

Authors:  Leo H Bonati; Jörg Ederle; Dominick J H McCabe; Joanna Dobson; Roland L Featherstone; Peter A Gaines; Jonathan D Beard; Graham S Venables; Hugh S Markus; Andrew Clifton; Peter Sandercock; Martin M Brown
Journal:  Lancet Neurol       Date:  2009-08-28       Impact factor: 44.182

Review 10.  The management of carotid restenosis: a comprehensive review.

Authors:  Francesco Stilo; Nunzio Montelione; Rosalinda Calandrelli; Marisa Distefano; Francesco Spinelli; Vincenzo Di Lazzaro; Fabio Pilato
Journal:  Ann Transl Med       Date:  2020-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.